Lantheus (NASDAQ:LNTH) Receives New Coverage from Analysts at Redburn Atlantic

Redburn Atlantic initiated coverage on shares of Lantheus (NASDAQ:LNTH - Free Report) in a research report report published on Tuesday morning, Marketbeat reports. The firm issued a buy rating and a $175.00 price objective on the medical equipment provider's stock.

Several other research analysts have also commented on LNTH. B. Riley raised their price target on Lantheus from $105.00 to $146.00 and gave the stock a buy rating in a research report on Thursday, July 25th. JMP Securities dropped their price objective on shares of Lantheus from $130.00 to $125.00 and set a market outperform rating for the company in a report on Thursday, August 1st. Leerink Partners increased their target price on shares of Lantheus from $106.00 to $127.00 and gave the stock an outperform rating in a report on Thursday, July 11th. Finally, Truist Financial decreased their price target on shares of Lantheus from $141.00 to $135.00 and set a buy rating for the company in a research report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Lantheus has an average rating of Moderate Buy and an average target price of $126.00.

Lantheus Price Performance

NASDAQ LNTH traded down $1.04 during trading hours on Tuesday, hitting $105.43. 592,722 shares of the company's stock traded hands, compared to its average volume of 1,045,903. The company has a market capitalization of $7.31 billion, a PE ratio of 16.10 and a beta of 0.51. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. Lantheus has a 52-week low of $50.20 and a 52-week high of $126.89. The firm's 50-day moving average is $101.14 and its 200-day moving average is $80.60.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). The company had revenue of $394.10 million during the quarter, compared to analysts' expectations of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. Lantheus's revenue for the quarter was up 22.5% on a year-over-year basis. During the same quarter last year, the company earned $1.40 earnings per share. Equities analysts forecast that Lantheus will post 6.03 EPS for the current fiscal year.

Insider Buying and Selling

In other Lantheus news, Director Gerard Ber sold 15,500 shares of the stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the transaction, the director now directly owns 21,221 shares of the company's stock, valued at $2,047,402.08. The sale was disclosed in a filing with the SEC, which is available at this link. In other Lantheus news, Director Gerard Ber sold 15,500 shares of the firm's stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now directly owns 21,221 shares in the company, valued at approximately $2,047,402.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Andrea Sabens sold 341 shares of the stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $79.77, for a total transaction of $27,201.57. Following the completion of the sale, the chief accounting officer now owns 62,557 shares in the company, valued at $4,990,171.89. The disclosure for this sale can be found here. Insiders sold 41,193 shares of company stock valued at $3,949,202 over the last ninety days. Corporate insiders own 1.50% of the company's stock.

Hedge Funds Weigh In On Lantheus

Large investors have recently bought and sold shares of the stock. Farallon Capital Management LLC lifted its stake in shares of Lantheus by 595.3% in the 1st quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider's stock valued at $92,316,000 after purchasing an additional 1,269,900 shares in the last quarter. Norges Bank acquired a new position in Lantheus during the fourth quarter valued at approximately $29,956,000. Swedbank AB purchased a new stake in Lantheus during the first quarter worth approximately $26,346,000. Nomura Holdings Inc. increased its position in shares of Lantheus by 105.3% in the fourth quarter. Nomura Holdings Inc. now owns 20,678 shares of the medical equipment provider's stock worth $1,282,000 after acquiring an additional 407,507 shares in the last quarter. Finally, Westfield Capital Management Co. LP raised its stake in shares of Lantheus by 25.3% in the 1st quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider's stock valued at $121,867,000 after acquiring an additional 394,837 shares during the period. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.